What’s Next? Five Things To Look Out For In June

Alvotech BSUFA Date Arrives Amid Setbacks; Viatris Eylea Trial Kicks Off

Jun 01 2023

• By Dean Rudge

Listen to this article

Generics Bulletin previews the most notable and anticipated events for June 2023.

What's Next Image — • Source: Citeline

Alvotech will at the end of June face yet another action date for its AVT02 proposed high-concentration biosimilar to Humira (adalimumab), the second of the company’s applications which contains additional information supporting a potential interchangeability designation, amid a series of setbacks brought on by good manufacturing practice deficiencies at the company’s Reykjavik manufacturing facility.

The 28 June Biosimilar User Fee Amendments of 2022 date for the interchangeability AVT02 application is just three days before...

More from Biosimilars

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C7
Oct 14 2026
• By Reed Miller
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C6
Oct 14 2026
• By Reed Miller
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
US Biosimilars
Oct 07 2026
An abbreviated licensure pathway for biologics was created by the 2009 Biologics Price Competition and Innovation Act. Biologics demonstrated to be biosimilar to or interchangeable with FDA-approved products can use the 351(k) biologics license application pathway. Biosimilars BLAs submitted under the 351(k) pathway have a 12 month user fee goal for FDA action. Updated weekly.
Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone
Jun 25 2026
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

More from Products

For Generics, A Victory Lap – And A Warning – On Drug Shortages
Oct 29 2025
Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.
GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps
Oct 27 2025
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
Biocon And Teva Sign Up To Biosimilars Forum
Oct 01 2025
Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.